Navigation Links
Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
Date:7/13/2009

NORCROSS, Ga., July 13 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced the submission of its formal 10 working day response to the Food and Drug Administration's ("FDA") administrative action, which was announced on June 26, 2009.

This formal 10-day response reiterates the Company's commitment to implement corrective actions that not only address the FDA's noted deficiencies but also establish a world-class quality system. The Company will provide its detailed remediation plan and timelines in its 30 working day response to the FDA no later than August 11, 2009.

"We take our regulatory responsibilities very seriously. We began our Quality Process Improvement Project in early 2009 to bring our quality system up to world-class standards," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. "We remain committed to completing this Project as quickly as possible."

Immucor previously announced that it had received a notice of intent to revoke its biologics license from the FDA with respect to its Reagent Red Blood Cells and Anti-E (Monoclonal) Blood Grouping Reagent products. This administrative action was based on a January 2009 inspection. The notice has a revised effective date of June 30, 2009.

The FDA has not ordered the recall or banned the sale of any of the Company's products.

New Product Surveillance and Improvement Department Established

The Company also announced today the creation of a Product Surveillance and Improvement Department to support the quality system initiative underway. With a focus on product quality, this new department will provide a single internal focal point to monitor quality issues, whether identified through internal or external sources, and initiate the appropriate corrective actions.

"We will continue to evaluate our operations and organization to ensure they are in line with our commitment to develop high quality systems," stated Dr. De Chirico. "Our new Product Surveillance and Improvement Department is an important example of our drive to modernize our quality approach."

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009
2. Immucor Announces Fiscal Year 2010 Guidance
3. Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009
4. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
5. Immucor Receives Subpoena From Department of Justice
6. Immucor Announces Fiscal Third Quarter Results
7. Immucor Announces New Vice President, Operations
8. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
9. Immucor Closes BioArray Acquisition
10. Immucor Schedules Fiscal 2009 Guidance Call
11. Immucor Responding to FDA Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... This campaign aims to provide a path to improved ... can control and change. , As nearly 795,000 Americans suffering from a new or ... States. Plus, with an estimated 129,000 of these people dying from stroke, it’s become ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... hosted members and suppliers for its inaugural Member Conference at the Paris Hotel ... of elevating the operational health of America’s healthcare providers. , The conference was ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
Breaking Medicine Technology: